TY - JOUR
AU - Bergfeld, Wilma
AB - Am J Clin Dermatol (2014) 15:217–230 DOI 10.1007/s40257-014-0077-5 EVIDENCE-BASED REVIEW Supenya Varothai Wilma F. Bergfeld Published online: 22 May 2014 Springer International Publishing Switzerland 2014 Abstract Results The medical treatments with the best level of Background Androgenetic alopecia (AGA) is one of the evidence classification for efficacy and safety for male most common chronic problems seen by dermatologists AGA are oral finasteride and topical minoxidil solution. worldwide. It is characterized by progressive hair loss, For female AGA, topical minoxidil solution appears to be especially of scalp hair, and has distinctive patterns of loss the most effective and safe treatment. The medical treat- in women versus men, but in both genders the central scalp ments corresponding to the next level of evidence quality is most severely affected. It often begins around puberty are some commonly used therapeutic non-FDA-approved and is known to effect self-esteem and the individual’s options including oral and topical anti-hormonal treat- quality of life. In contrast to the high prevalence of AGA, ments. Surgical treatment of follicular unit hair transplan- approved therapeutic options are limited. In addition to the tation is an option in cases that have failed medical scarce pharmacologic treatments, there are numerous treatment although 
TI - Androgenetic Alopecia: An Evidence-Based Treatment Update
JF - American Journal of Clinical Dermatology
DO - 10.1007/s40257-014-0077-5
DA - 2014-05-22
UR - https://www.deepdyve.com/lp/springer-journals/androgenetic-alopecia-an-evidence-based-treatment-update-yJaxG79xCv
SP - 217
EP - 230
VL - 15
IS - 3
DP - DeepDyve
ER -